Can I read Revumenib Efficacy in KMT2Ar Leukemia on EtoBox?

Revumenib Efficacy in KMT2Ar Leukemia by yunzi1516 is a document available to read on EtoBox.

What is Revumenib Efficacy in KMT2Ar Leukemia about?

The document discusses the efficacy and safety of revumenib in treating KMT2Ar acute leukemia, highlighting results from the AUGMENT-101 trial which showed a 63% overall response rate. It also mentions the ongoing SAVE trial combining revumenib with venetoclax and decitabine-cedazuridine, indicating promising outcomes in terms of response rates and minimal residual disease. Additionally, adverse events associated with the treatments are documented, emphasizing the need for careful monitoring.

Author

yunzi1516

Language

EN